

Please replace the abstract at page 82 with the following new abstract:

ABSTRACT OF THE DISCLOSURE

Methods and compositions are provided for the prevention or treatment of myelin disorders which involve modulating Ulip/CRMP activity. In particular, a method for the prevention or treatment of myelin disorders is provided which comprises administering to a patient in need of such treatment a therapeutically effective amount of an agent which modulates Ulip/CRMP activity. The agent can be a Ulip/CRMP protein, a nucleic acid coding for a Ulip/CRMP protein, an anti-sense sequence capable of specifically hybridizing with the nucleic acid, an antibody directed against the Ulip/CRMP protein, or an aptamer capable of binding the protein, and a pharmacologically acceptable carrier.